BCL2 and Waldenstrom macroglobulinemia: Venetoclax has single-agent activity in a broad range of lymphoid neoplasms, with MCL and Waldenstrom macroglobulinemia demonstrating the greatest intrinsic sensitivity to BCL2 inhibition.